YahooSeptember 28, 2026 at 9:41 AM NY29 Days Ago
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
